Jeremy Bonzo, MD
Urology · Ashland, KYNPI 1447511332
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Neotract Inc. at 39.4% of the total. Reporting peaked in 2019 at $3,910 and has fallen 77.5% since, to $880 in 2025.
Across 191 payments — averaging $38.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$3K
- Astellas Pharma US Inc$1K
- Boston Scientific$1000
- Pfizer$407
- Antares Pharma, Inc.$242
- Procept Biorobotics Corporation$183
- plus $2K from 21 others
What the payments were for
- Travel & lodging$3,14142%
- Food & beverage$3,72950%
- Education$5397%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 14 | $2,920 |
| Astellas Pharma US Inc | 50 | $1,152 |
| Boston Scientific | 9 | $1,000 |
| Pfizer | 23 | $407 |
| Antares Pharma, Inc. | 11 | $242 |
| Procept Biorobotics Corporation | 6 | $183 |
| Intuitive Surgical | 2 | $166 |
| AbbVie | 11 | $157 |
| Myriad Genetic Laboratories, Inc. | 9 | $155 |
| Endo USA, Inc. | 7 | $142 |
| Bayer | 7 | $124 |
| Endo Pharmaceuticals Inc. | 7 | $119 |
| Coloplast | 5 | $75 |
| Johnson & Johnson | 4 | $74 |
| Axonics, Inc. | 5 | $74 |
| Conmed Corporation | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| Laborie Medical Technologies Corp. | 1 | $50 |
| Urovant Sciences Inc | 3 | $44 |
| Halozyme Inc | 2 | $42 |
| Myovant Sciences Inc. | 2 | $26 |
| Medtronic | 1 | $22 |
| 180 Medical, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,723
- GENERAL KIDNEY STONE DISEASE$813
How this compares
$7,409 in reported general payments places this provider in the 75th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 20 | $281,991 |
| GemtesaVibegron | 21 | $19,673 |
| MyrbetriqMirabegron | 23 | $16,344 |
| Testosterone | 39 | $7,347 |
| Estradiol | 65 | $3,135 |
| Tamsulosin Hcl | 328 | $2,640 |
| Testosterone Cypionate | 103 | $2,461 |
| Oxybutynin Chloride ErOxybutynin Chloride | 167 | $1,996 |
| Methenamine Hippurate | 30 | $1,636 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,253 |
| Cephalexin | 236 | $1,119 |
| Finasteride | 106 | $917 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $728 |
| Cefpodoxime Proxetil | 14 | $517 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,152 | $298,33443 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $53 | $19,67321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 139 urology providers in Kentucky.
Other urology in Ashland
- William BoykinAshland$5K
- Brian DefadeAshland$4K
- Justin DixonAshland$4K
- Daniel HettelAshland$3K
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.